Survival benefit with capecitabine/docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial

Clinical Breast Cancer

Volumn 5, Issue 4, 2004, Pages 273-278

  Miles, David ^a   Vukelja, Svetislava ^b   Moiseyenko, Vladimir ^c   Cervantes, Guadalupe ^d   Mauriac, Louis ^e   Van Hazel, Guy ^f   Liu, Wing Yiu ^g   Ayoub, Jean Pierre ^h   O'Shaughnessy, Joyce A ⁱ  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^d CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^e INSTITUT BERGONIÉ   (France)

^f Perth Oncology   (Australia)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h NOTRE DAME HOSPITAL   (Canada)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anthracyclines; Combination therapy; Taxanes; Vinorelbine

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 9444288775     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.030     Document Type: Article

References (17)

1. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17:1413-1424.
2. Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003; 82(suppl 1):S9 (Abstract #10).
3. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
4. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000; 34:293-296.
5. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
6. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma. Cancer 2001; 92:1759-1768.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
8. Fumoleau P, Largillier P, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2003; 40:536-542.
9. Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: results of a phase III study [Research in Brief]. Clin Breast Cancer 2003; 3:375-377.
10. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
11. Fujimoto-Ouchi K, Yasuno H, Tanaka Y. Schedule-dependency of antitumor activity in combination therapy with capecitabine (Xeloda®) and docetaxel in breast cancer models. Proc Am Assoc Cancer Res 2001; 42a.
12. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 12:2812-2823.
13. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer; an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
14. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16:3720-3730.
15. Koroleva I, Wojtukiewicz M, Zaluski J, et al. Preliminary results of a phase III randomized trial of Taxotere (T) and doxorubicin (A) given in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; 20:30a (Abstract # 117).
16. Reyes S, Torrecillas L, Acosta A, et al. Capecitabine, and taxanes: combination versus sequential therapy in anthracycline-pretreated metastatic breast cancer (MBC): findings from the Mexican Oncology Study Group (MOSG) phase III trial. Eur J Cancer 2003; 1(suppl 5):S136 (Abstract #447).
17. Torrecillas L, Cortes P, Tokunaga J, et al. Capecitabine monotherapy or combined with taxanes: early results in quality of life in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:749 (Abstract #3011).